Badri Modi, M.D.

(877) 460-4673
Badri Modi, M.D.
Dermatologist
Clinical Expertise
  • Skin Cancer
  • Graft-versus-host Disease
  • Medication Reactions
  • Supportive Dermato-oncology
Research Area
  • Immunotherapy for Skin Cancer
  • Graft-versus-host Disease
Academic Appointments
  • Associate Clinical Professor, Division of Dermatology, Department of Surgery
Clinical Teams
Cutaneous Lymphoma Program
Dermatology
Surgery

Dermatologists play an important role in the primary and supportive care of cancer patients.

As a dermatologist working at City of Hope, Badri Modi, M.D. focuses on identification and management of high risk skin cancers such as melanoma. Furthermore, he cares for patients with cutaneous complications from the treatment of internal malignancies like leukemia and breast cancer, which can be as or more devastating than the underlying disease.

Dr. Modi received his medical degree from Yale University, completed an internship in internal medicine at The Massachusetts General Hospital and completed dermatology residency at the University of Pennsylvania, where he served as chief resident in his final year. He has published numerous peer-reviewed articles related to cancer research and clinical care.

Dr. Modi finds fulfillment in using his knowledge and skills to help others, especially in difficult cases. He chose City of Hope “to work with patients with challenging cancers.”

Location

Education & Experience

Degrees

  • 2012, M.D., Yale University School of Medicine
  • 2007, B.S., Emory University

Fellowship

  • 2010–2011, Research Fellow, Laboratory of Michael Girardi, New Haven, CT

Residency

  • 2013–2016, Resident in Dermatology, Hospital of the University of Pennsylvania, Philadelphia, PA

Internship

  • 2012–2013, Intern in Medicine, Massachusetts General Hospital, Boston, MA

Awards & Memberships

Awards

  • 2015, Resident International Grant, American Academy of Dermatology
  • 2015, Medical Student Teaching Award Winner, Edward E. Bondi Dermatologic Society, University of Pennsylvania
  • 2013, Centers of Expertise in Global & Humanitarian Health Travel Grant, Massachusetts General Hospital
  • 2012, William Gardner Prize for Most Outstanding Thesis, Yale University School of Medicine
  • 2011, Richard K. Gershon Student Research Fellowship, Yale University School of Medicine
  • 2007, Phi Beta Kappa, Emory University
  • 2007, President of the Year, for role as President of the Indian Cultural Exchange, Emory University

Publications

  • Armenian SH, Lindenfeld L, Iukuridze A, Echevarria M, Bebel S, Coleman C, Nakamura R, Abdullah F, Modi B, Oeffinger KC, Emmons KM, Marghoob AA, Geller AC. Technology-Enabled Activation of Skin Cancer Screening for Hematopoietic Cell Transplantation Survivors and their Primary Care Providers (TEACH). BMC Cancer. 2020 Aug 3;20(1):721. doi: 10.1186/s12885-020-07232-2. PMID: 32746799.
  • Rischin D, Migden MR, Lim AM, Schmults CD, Khushalani NI, Hughes BGM, Schadendorf D, Dunn LA, Hernandez-Aya L, Chang ALS, Modi B, Hauschild A, Ulrich C, Eigentler T, Stein B, Pavlick AC, Geiger JL, Gutzmer R, Alam M, Okoye E, Mathias M, Jankovic V, Stankevich E, Booth J, Li S, Lowy I, Fury MG, Guminski A. Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: Primary Analysis of fixed-dosing, long-term outcome of weight-based dosing. J Immunother Cancer. 2020 Jun;8(1):e000775. doi: 10.1136//jitc-2020-000775. PMID: 32554615
  • Ali H, Salhotra A, Modi B, Nakamura R. Ruxolitinib for the treatment of graft-versus-host disease. Expert Rev Clin Immunol. 2020 Apr;16(4):347-359. doi: 10.1080/1744666X.2020.1740592. Epub 2020 Apr 1. PMID: 32153201
  • Virgen CA, Nguyen TA, Di Raimondo C, Amini A, Margolin KA, Parekh V, Abdulla FR, Modi B. Bullous pemphigoid associated with cemiplimab therapy in a patient with locally advanced cutaneous squamous cell carcinoma. JAAD Case Rep. 2020 Feb 19:6(3):195-197. doi: 10.1016/j.jdcr.2020.01.008. eCollection 2020 Mar. PMID: 32149176
  • Shinde A, Verma V, Jones BL, Li R, Glaser S, Freeman M, Melstrom L, Kang R, Parvathaneni U, Modi B, Amini A. The Effect of Time to Postoperative Radiation Therapy on Survival in Resected Merkel Cell Carcinoma. Am J Clin Oncol 2019 Aug;42(8):636-642. doi: 10.1097/COC.0000000000000565. PMID: 31246585
  • Migden M, Rischin D, Schmults C, Guminski A, Hauschild A, Lewis K, Chung C, Hernandez-Aya L, Lim A, Chang A, Rabinowits G, Thai A, Dunn L, Hughes B, Khusalani N, Modi B, Schadendorf D, Gao B, Seebach F, Li S, Li J, Mathias M, Booth J, Mohan K, Stankevich E, Babiker H, Brana I, Gil-Martin M, Homsi J, Johnson M, Moreno V, Niu Jiaxin, Owonikoko T, Papadopoulos K, Yancopoulos G, Lowry I, Fury M. PD-1 blockade with Cemiplimab in advanced cutaneous squamous cell carcinoma. N Engl J Med. 2018 Jul 26;379(4):341-351. doi: 10.1056/NEJMoa1805131. Epub 2018 Jun 4. PMID: 29863979. Impact Factor: 72.406
  • Modi B, Hernandez-Henderson M, Yang D, Klein J, Dadwal S, Kopp E, Huelsman K, Mokhtari S, Ali H, Malki MMA, Spielberger R, Salhotra A, Parker P, Forman S, Nakamura R. Ruxolitinib as Salvage Therapy for Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2019 Feb;25(2):265-269. doi: 10.1016/j.bbmt.2018.09.003. Epub 2018 Sep 8. PMID: 30201397
  • Ghosh K, Modi B, James WD, Capell BC. BAP1: Case Report and Insight into a Novel Tumor Suppressor. BMC Dermatol. 2017 Nov 22; 17(1):13. doi: 10.1186/s12895-017-0065-63. PMID: 29166932
  • Sobanko JF, Da Silva D, Chiesa Fuxench ZC, Modi B, Shin TM, Etzkorn JR,Samimi SS, Wanat KA, Miller CJ. Preoperative telephone consultation does not decrease patient anxiety before Mohs micrographic surgery. J Am Acad Dermatol. 2017 March;76(3): 519-526. doi: 10.1016/j.jaad.2016.08.027. PMID: 27923500. Impact factor 4.449
  • Tracey E, Modi B, Micheletti R. Pemetrexed-induced pseudocellulitis reaction with eosinophilic infiltrate on skin biopsy. Am J Dermatopathol. 2017 Jan; 39(1):e1-e2. doi:10.1097/DAD.000000000000645. PMID: 27415636. Impact factor: 1.426

Ratings & Reviews

Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with five stars being the highest.
4.9
Show respect for what you say
4.8
Provider explain in way you understand
4.8
Provider listen carefully to you
4.7
Recommend this provider office
4.7
Spend enough time with you
4.7
Rate provider 0-10
4.6
Know important info medical history
03/30/26
Dr Modi is very kind and efficient. A very good doctor! - Verified patient
03/20/26
DR. MODI AND TEAM ARE GREAT! - Verified patient
03/20/26
Dr. Modi & his team are Excellent! - Verified patient
03/20/26
Dr. Modi is Wonderful. He is very knowledgeable, explains what he's going to do, listens to my concerns & sometimes gives me choices for a type of treatment. He is sensitive to the fact that I'm a "pain wimp". If he biopsies something he already knows it is skin cancer and he promptly call me when he has the biopsy results then explains treatment plan. - Verified patient
03/19/26
Dr. Modi is an excellent physician/caregiver. He communicates in a clear, friendly manner; and is thorough, kind and caring in discussing diagnosis and treatment in a two-way manner. He has performed multiple surgeries on me. He is one of the best doctors I have been treated by in my lifetime. He represents City of Hope extremely well and should be thanked and recognized for his great work. - Verified patient